DXCM Add to watchlist $74.12 2.23 (-2.92%) Last updated: Jul 15, 2026 06:01
52-Week Range
$74.12
$54.11 $74.12 $89.98

Fundamentals Overview

DexCom, Inc. is in the middle of its 52-week range with premium valuation, trending downward today.

Valuation premium

P/E 31.4 PEG 0.42 P/B 9.65 P/S 5.94

Intrinsic value (DCF)

-38.7% downside vs price

Profitability

Net margin 19.3%

Risk (Beta)

1.45 — higher vol

Earnings & growth

EPS $2.36 Rev -5.4% Profit -25.4% vs prior qtr

BullzEye Analysis

Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Hold — 54% confidence Risk: High Volatility — Beta 1.45. Consider smaller position size due to higher beta.

Supporting (Buy):

Analyst grade: B+ · 3M vs S&P 500: +7.8% · 3M vs Healthcare sector: +10.5%

Pressures (Sell):

DCF 38.7% downside vs price · Beta 1.45 (elevated)

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$28.60B
P/E (TTM)
31.36
EPS (TTM)
$2.36
Dividend Yield
N/A
52-Week Range
$54.11 - $89.98
Volume vs Avg
N/A
Beta
1.45

About

DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM...
Sector: Healthcare
Headquarters: US
Employees: 11,100
IPO Date: Apr 2005
Beta: 1.45 (More volatile than market)

Ratings & Grades at a Glance

Overall rating: B+. Recent institutional grades: mixed. Current institutional positions: Buy: 18, Equal Weight: 1, Outperform: 4, Overweight: 3, Underweight: 4.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $45.42; current price is $74.12. That’s a -38.7% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) 31.36
DCF value (model) $45.42 (-38.7% vs price)
PEG (TTM) 0.42
P/B (TTM) 9.65
P/S (TTM) 5.94
P/FCF (TTM) 20.01
Liquidity & enterprise
Current Ratio (TTM) 1.95
Quick Ratio (TTM) 1.64
Cash Ratio (TTM) 0.5
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) 19.31%
Gross margin (TTM) 61.84%
Operating margin (TTM) 21.45%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for DXCM.

Analyst Sentiment at a Glance

B+ Sentiment Mixed
Buy 18Equal Weight 1Outperform 4Overweight 3Underweight 4
1 upgrade, 1 downgrade
Price Target Consensus
Current $74.12
Median $85.50
Consensus $83.80
Low consensus $64.00
High consensus $95.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
Deutsche Bank maintain Buy Buy 2026-06-23
Piper Sandler maintain Overweight Overweight 2026-06-15
TD Cowen maintain Buy Buy 2026-06-10
Mizuho maintain Outperform Outperform 2026-06-09
Stifel maintain Buy Buy 2026-06-05
Citigroup maintain Buy Buy 2026-05-28
Barclays maintain Underweight Underweight 2026-05-18
Canaccord Genuity maintain Buy Buy 2026-05-18
B of A Securities maintain Buy Buy 2026-05-18
Citigroup maintain Buy Buy 2026-05-04
Barclays maintain Underweight Underweight 2026-05-01
TD Cowen maintain Buy Buy 2026-05-01
Canaccord Genuity maintain Buy Buy 2026-05-01
Citigroup maintain Buy Buy 2026-03-11
BTIG maintain Buy Buy 2026-03-09
BTIG maintain Buy Buy 2026-02-25
Truist Securities maintain Buy Buy 2026-02-17
Mizuho maintain Outperform Outperform 2026-02-13
BTIG maintain Buy Buy 2026-02-13
Barclays maintain Underweight Underweight 2026-02-13
Wells Fargo maintain Overweight Overweight 2026-02-13
Canaccord Genuity maintain Buy Buy 2026-02-13
Barclays downgrade Equal Weight Underweight 2026-01-12
Bernstein maintain Outperform Outperform 2026-01-09
Mizuho maintain Outperform Outperform 2025-12-17
Citigroup maintain Buy Buy 2025-12-11
Morgan Stanley upgrade Equal Weight Overweight 2025-12-02
Morgan Stanley maintain Equal Weight Equal Weight 2025-11-10
Argus Research maintain Buy Buy 2025-11-07
Truist Securities maintain Buy Buy 2025-11-03